Insights from 2023 ASCO® Annual Meeting
Playback speed
10 seconds
ASCO® 2023 Insights: "Zanubrutinib + Obinutuzumab vs. Obinutuzumab in Patients With R/R FL - Updated Analysis of the ROSEWOOD Study"
508 views
June 9, 2023
Comments 0
Login to view comments.
Click here to Login
Hematology